Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR …
TS Mok, Y Cheng, X Zhou, KH Lee… - Journal of Clinical …, 2018 - ascopubs.org
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and …
TS Mok, Y Cheng, X Zhou, KH Lee… - Journal of Clinical …, 2018 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> ARCHER 1050, a randomized, open-
label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with …
label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with …
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR …
TS Mok, Y Cheng, X Zhou, KH Lee… - Journal of Clinical …, 2018 - europepmc.org
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and …
gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and …
[PDF][PDF] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - J Clin Oncol, 2018 - academia.edu
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naıve patients with advanced non–small-cell lung cancer (NSCLC) and …
gefitinib in treatment-naıve patients with advanced non–small-cell lung cancer (NSCLC) and …
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR …
TS Mok, Y Cheng, X Zhou, KH Lee… - Journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and …
gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and …